Current Healthcare Challenges & Novel Ideas Around Neuromodulation

10 March 2020

Boğaziçi-BME/Lifesci & Inovita & ISEK Joint Seminar


Current Healthcare Challenges & Novel Ideas Around Neuromodulation  

10 March 2020 (Tuesday);   13.00 – 14.00



Lone Star Neuromodulation, Inc


Biomedical Engineering Institute, AZ-19,  Boğaziçi University Kandilli Campus, Istanbul

About the Seminar:

Most of the present day diagnostic techniques are based on chemistry, except for imaging techniques. This is not surprising, as the current treatment options and modalities originate almost entirely from pharmaceutical industries. In essence, human body is an electrical system. Had the foundation of medical science been based on electricity, diagnostics and treatment options could have been much different today. But, it is time to shift this focus in favor of electricity, which is fundamentally the way the body works.

So, we need data. Collecting and integrating a broad spectrum of data around health and disease may reveal insights into understanding what “healthy” means and what happens during the transition between healthy and not healthy.

We need new sources of data to provide biomarkers to obtain long-term representation of functions, and seek for insight into functional changes through the variations of those biomarkers. If we can enable precise monitoring of progressive diseases early on, in a multi-dimensional manner (from a single cell to the whole body) and integrate varied data streams to map those to disorders, we may arrive at a reliable image of actionable information covering causes and effects. This may then be applied towards developing preventive or therapeutic solutions for diseases that are believed to be difficult or not curable in present day.

The dream is about changing healthcare at its core and preventing disorders instead of treating them after they strike.

This is a long journey and it requires a paradigm shift in thinking and comprehensive technologies, such as new tools and capabilities to gather informative, high precision data. For that, we would need analytical expertise, computing power with machine-learning capabilities, new types of sensors and interventional products, preferably non-invasively, all with guidance from clinicians and scientists to dig up meaningful data.

We may then be able to develop solutions by ascertaining whether an intervention is indeed decelerating or reversing disease progression, effectively addressing the causes, and preventing disorders all together before the onset of any early symptoms.

Once we arrive at this point, I am certain that the engineering challenges will trigger innovation and new technologies and products from macroscopic to microscopic as would be dictated by the needs of the desired applications. I suspect, the early versions of these solutions would likely be relying on ubiquitous and scalable cloud computing, long-range and safe wireless power transfer, energy harvesting, nanotechnology, molecular-scale manufacturing techniques, and will give rise to Internet of Living Things.   

About the Speaker:

Serdar Kiykioglu received his BSc.EE and MSc. EE degrees from Istanbul Technical University in 1980 and 1982 respectively. He was a member of the core team that started the YITAL Semiconductor Technology Research  Lab at The National Research Institute of Electronics and Cryptology of Turkey shortly UEKAE (formerly TUBITAK-MAM).

Since 1989 Mr. Kiykioglu has been pursuing his career in the United States, assuming progressive R&D and management roles. In 2009 he joined St. Jude Medical (now Abbott) to work on innovative technologies and products in the field of implantable neuromodulation systems for the treatment of neurological disorders. Mr. Kiykioglu actively promotes the use of electrical neuromodulation as an alternative to pharmaceuticals in the treatment of neurological disorders such as chronic pain, migraine, Parkinson’s, dementia, dystonia, and depression, with a keen focus on combating the opioid crisis.

To pursue his goals, in 2014, he co-founded Lone Star Neuromodulation, Inc., in Texas, USA, and has been serving as the Chief Technology Officer. The platform developed by Lone Star Neuromodulation, Inc., is the first generic neuro stimulator system in the world intended to accelerate novel medical research and offer affordable new therapy modalities. In addition to electrical neuromodulation,

Mr. Kiykioglu participates actively in research including high speed telecommunication systems, Internet of Things; cloud computing, machine learning, and artificial intelligence.